{"acquisitions":[],"changes":[],"country":"US","description":"Enalare Therapeutics is developing ENA-001, a patent-protected breathing stimulant for acute respiratory depression. Target indications include opioid-overdose respiratory depression, post-operative respiratory compromise, and apnea of prematurity in infants. The new chemical entity is positioned to provide a non-opioid pharmacologic option for emergency and inpatient settings.","domain":"enalare.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":40.349695,"lng":-74.659738,"location":"PRINCETON, New Jersey","multiples":[],"name":"ENALARE THERAPEUTICS INC","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":2499118,"connectionsAmong":[],"currency":"USD","date":"2025-01-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"enalare-com-2025-01-01-grant","source":{"fact":"round","publisher":"sbir","retrievedAt":"2026-05-02","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"enalare-com","sources":[{"fact":"round","publisher":"sbir","retrievedAt":"2026-05-02","status":"attributed","url":null},{"fact":"existence","publisher":"enalare.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://enalare.com"},{"fact":"description","publisher":"enalare.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://enalare.com"}],"stage":null,"stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["WordPress 7.0","Apache HTTP Server 2.4.41","Yoast SEO 27.6","Ubuntu","Google Tag Manager","Google Tag Manager for WordPress 1.22.3","Slider Revolution","jQuery Migrate 3.4.1","PHP","Contact Form 7 6.1.6","MySQL","apache 2.4.41"],"totalRaisedUsd":2499118,"traction":[],"updatedAt":"2026-05-02","valuations":[]}